公开(公告)号：US20110059247A1

公开(公告)日：2011-03-10

申请号：US12736718

申请日：2009-05-14

申请人： Junichi Kuzusako ,  Masanobu Yamamoto ,  Akira Ookubo ,  Toshihiro Kamewa ,  Tomohide Koizumi ,  Kazuma Tamura ,  Takeshi Matsui

发明人： Junichi Kuzusako ,  Masanobu Yamamoto ,  Akira Ookubo ,  Toshihiro Kamewa ,  Tomohide Koizumi ,  Kazuma Tamura ,  Takeshi Matsui

IPC分类号： B05D3/02 ,  B05C13/00

CPC分类号： B29C67/0081 ,  B22C7/02 ,  B22C9/00 ,  B29C64/165

摘要： [Object] To form a modeled object with high accuracy.[Solving Means] A powder transfer mechanism (16) laminates powder layers containing water-soluble powder as a main component one by one at a modeling portion (14). An inkjet line head (17) injects a water-based ink that dissolves the powder in an area of an uppermost layer of the powder layers laminated by the powder transfer mechanism (16), the area corresponding to a cross-sectional shape of a modeled object. Then, a heater (18) heats the powder for each layer of the powder layers. Further, the heater (18) heats the powder after the water-based ink is injected by the inkjet line head (17) or before the water-based ink is injected by the inkjet line head (17). The present invention can be applied to a modeling apparatus, for example.

摘要翻译： [对象]以高精度形成模型化对象。 [解决方案]粉末转移机构（16）在建模部分（14）逐个层叠含有水溶性粉末作为主要成分的粉末层。 喷墨线头部（17）将通过粉末转印机构（16）层叠的粉末层的最上层的区域中的粉末溶解的水性油墨注入到与模型化的截面形状对应的区域 目的。 然后，加热器（18）加热各层粉末层的粉末。 此外，加热器（18）在通过喷墨线头（17）喷射水基油墨之后或在喷墨线头（17）喷射水性油墨之前加热粉末。 例如，本发明可以应用于建模装置。

公开(公告)号：US20100260856A1

公开(公告)日：2010-10-14

申请号：US12745851

申请日：2008-09-08

申请人： Masashi Konishi ,  Shouichi Oonishi ,  Akira Ookubo ,  Masashi Yunoki ,  Ariumi Kawamoto ,  Kanako Hattori

发明人： Masashi Konishi ,  Shouichi Oonishi ,  Akira Ookubo ,  Masashi Yunoki ,  Ariumi Kawamoto ,  Kanako Hattori

IPC分类号： A61K9/14 ,  A61K31/167 ,  A61P3/10

CPC分类号： A61K9/1611 ,  A61K9/1676 ,  A61K47/02

摘要： The present invention provides a core particle for a pharmaceutical preparation which features the requisite properties of a core particle, and which has enough chemical stability, and in which reactivity with the drug (an active pharmaceutical ingredient) is limited or prevented. More specifically, the present invention relates to a core particle wherein a film containing an active pharmaceutical ingredient can be formed on the surface thereof, and (1) the core particle comprises a pharmaceutically acceptable inorganic material, (2) the inorganic material is poorly soluble in water, and (3) pH of a solution of the inorganic material is 5 to 8.

摘要翻译： 本发明提供了具有核心颗粒必需性质并具有足够化学稳定性的药物制剂的核心颗粒，其中与药物（活性药物成分）的反应性受到限制或预防。 更具体地说，本发明涉及一种核心颗粒，其中可以在其表面上形成含有活性药物成分的膜，（1）芯颗粒包含药学上可接受的无机材料，（2）无机材料难溶 在水中，（3）无机材料的溶液的pH为5〜8。

公开(公告)号：US6013238A

公开(公告)日：2000-01-11

申请号：US109415

申请日：1998-07-02

申请人： Hiroki Murata ,  Masayoshi Suzue ,  Akiyoshi Kawaguchi ,  Fauzi Faustinus ,  Toshihiro Kamewa ,  Tomohide Koizumi

发明人： Hiroki Murata ,  Masayoshi Suzue ,  Akiyoshi Kawaguchi ,  Fauzi Faustinus ,  Toshihiro Kamewa ,  Tomohide Koizumi

IPC分类号： C01G23/00 ,  C04B35/462 ,  C04B35/478 ,  C08K7/02 ,  C22C49/00 ,  C30B25/00 ,  C01G23/08 ,  C01F7/04

CPC分类号： C22C49/00 ,  C01G23/003 ,  C04B35/462 ,  C04B35/478 ,  C08K7/02 ,  C30B25/005 ,  C30B29/32 ,  B22F2998/00 ,  C01P2002/72 ,  C01P2004/03 ,  C01P2004/10 ,  C01P2004/61 ,  C01P2004/62 ,  C01P2006/14 ,  Y10T428/12493

摘要： This invention aims to provide titanate whiskers which are excellent in heat resistance, chemical resistance and reinforcing effect and are low in coefficient of thermal conductivity.The titanate whiskers of the invention are those represented by the formulaA.sup.I.sub.v A.sup.II.sub.w M.sup.II.sub.x M.sup.III.sub.y Ti.sub.8-z O.sub.16wherein A.sup.I is at least one member selected from alkali metals, A.sup.II is Ba, M.sup.II is at least one member selected from the group consisting of Mg, Co, Ni, Zn, Cu and Mn, M.sup.III is at least one member selected from the group consisting of Al, Sc, Cr, Fe and Ga, and v, w, x, y and z are real numbers which fulfill 0.5.ltoreq.2x+y.ltoreq.2.5, 2x+y=v+2w, and z=x+y.

摘要翻译： 本发明的目的在于提供耐热性，耐化学性和增强效果优异且导热系数低的钛酸酯晶须。 本发明的钛酸酯晶须是由下式表示的钛酸酯晶须：其中Al为选自碱金属中的至少一种，AII为Ba，MII为选自Mg，Co，Ni，Zn，Cu中的至少一种 Mn，MIII为选自Al，Sc，Cr，Fe和Ga中的至少一种，v，w，x，y和z为满足0.5≤x+ y < 2.5，2x + y = v + 2w，z = x + y。

公开(公告)号：US4931289A

公开(公告)日：1990-06-05

申请号：US271329

申请日：1988-11-15

申请人： Takeshi Suzuki ,  Mineaki Kabayama

发明人： Takeshi Suzuki ,  Mineaki Kabayama

IPC分类号： C01F7/02 ,  A61K33/06 ,  A61K33/08 ,  A61P3/00 ,  B01J20/08

CPC分类号： A61K33/08 ,  A61K33/06

摘要： An oral phosphate ion-adsorbing agent containing as an effective component a boehmite-type aluminum hydroxide which is represented by the formulaAlO(OH).multidot.nH.sub.2 Owherein 0.ltoreq.n

公开(公告)号：US11866611B2

公开(公告)日：2024-01-09

申请号：US16770030

申请日：2018-12-06

申请人： TOMITA PHARMACEUTICAL CO., LTD.

发明人： Naoyuki Kitamura ,  Akihito Bando ,  Yuta Tsumura ,  Shota Minami

IPC分类号： C23C4/134 ,  C09D1/00 ,  C09D5/03 ,  A61L27/06 ,  A61L27/32 ,  A61L27/56 ,  C01B25/32 ,  C23C4/04

CPC分类号： C09D5/032 ,  A61L27/06 ,  A61L27/32 ,  A61L27/56 ,  C01B25/32 ,  C09D1/00 ,  C09D5/031 ,  C23C4/04 ,  C23C4/134 ,  A61L2420/02 ,  A61L2430/24 ,  C01P2002/72 ,  C01P2004/02 ,  C01P2004/61 ,  C01P2006/11 ,  C01P2006/14 ,  C01P2006/16

摘要： The purpose of the present invention is to provide a plasma spray material which is capable of forming a hydroxyapatite film that exhibits high adhesion strength with respect to substrates such as metal substrates. When used as a plasma spray material, hydroxyapatite powder having a modal diameter of 550-1000 nm in a pore diameter of at most 5000 nm as measured by a mercury intrusion method is capable of forming a hydroxyapatite film that exhibits high adhesion strength with respect to substrates such as metal substrates.

公开(公告)号：US11124420B2

公开(公告)日：2021-09-21

申请号：US15034912

申请日：2014-11-07

申请人： TOMITA PHARMACEUTICAL CO., LTD.

发明人： Yuuta Tsumura ,  Kazuki Kamai ,  Yukinori Konishi ,  Kazuhiko Tamagawa

IPC分类号： C01B33/24 ,  A61K9/51 ,  A23L29/00 ,  A61K9/16 ,  A61K47/02

摘要： Provided is powdered gyrolite-type calcium silicate that has a relatively large particle size, yet is endowed with both a high oil absorption and a high particle strength. The powdered gyrolite-type calcium silicate has (1) an oil absorption of at least 2.8 mL/g, (2) an average particle diameter of at least 40 μm, and (3) in treatment where the gyrolite-type calcium silicate is charged into a laser diffraction-type particle size analyzer within the range of a diffraction volume of from 0.1 to 0.6 and circulated at a flow rate of 32.5 mL/s for 5 minutes, a percent change in average particle diameter following treatment with respect to average particle diameter before treatment of 15% or less.

公开(公告)号：US10517825B2

公开(公告)日：2019-12-31

申请号：US15578113

申请日：2016-05-27

申请人： TOMITA PHARMACEUTICAL CO., LTD.

发明人： Takanori Taniwaki ,  Kazuki Kamai ,  Yuuta Tsumura ,  Daichi Masaki

IPC分类号： A61K9/14 ,  A61K47/02 ,  A61K9/20 ,  A61K31/202 ,  C01B33/24 ,  A61K8/25 ,  A61K8/02 ,  A61K33/06 ,  A61K35/60 ,  A61Q19/00

摘要： Provided is a powder composition containing an oily substance, the powder composition having good oxidation stability and excellent compression moldability. The powder composition containing an oily substance contains a powdery calcium silicate-based material, and an oily substance impregnated into the material. In the material, a cumulative pore volume for a pore size of 10 to 70 nm is 1.1 cc/g or more, and a cumulative pore volume for a pore size of 70 to 500 nm is 2.0 cc/g or less.

公开(公告)号：US09149434B2

公开(公告)日：2015-10-06

申请号：US12745851

申请日：2008-09-08

申请人： Masashi Konishi ,  Shouichi Oonishi ,  Akira Ookubo ,  Masashi Yunoki ,  Ariumi Kawamoto ,  Kanako Hattori

发明人： Masashi Konishi ,  Shouichi Oonishi ,  Akira Ookubo ,  Masashi Yunoki ,  Ariumi Kawamoto ,  Kanako Hattori

IPC分类号： A61K9/16 ,  A61K47/02

CPC分类号： A61K9/1611 ,  A61K9/1676 ,  A61K47/02

摘要： The present invention provides a core particle for a pharmaceutical preparation which features the requisite properties of a core particle, and which has enough chemical stability, and in which reactivity with the drug (an active pharmaceutical ingredient) is limited or prevented. More specifically, the present invention relates to a core particle wherein a film containing an active pharmaceutical ingredient can be formed on the surface thereof, and (1) the core particle comprises a pharmaceutically acceptable inorganic material, (2) the inorganic material is poorly soluble in water, and (3) pH of a solution of the inorganic material is 5 to 8.

摘要翻译： 本发明提供了具有核心颗粒必需性质并具有足够化学稳定性的药物制剂的核心颗粒，其中与药物（活性药物成分）的反应性受到限制或预防。 更具体地说，本发明涉及一种核心颗粒，其中可以在其表面上形成含有活性药物成分的膜，（1）芯颗粒包含药学上可接受的无机材料，（2）无机材料难溶 在水中，（3）无机材料的溶液的pH为5〜8。

公开(公告)号：US08668852B2

公开(公告)日：2014-03-11

申请号：US13203143

申请日：2010-02-26

申请人： Akira Ookubo ,  Tomohide Koizumi ,  Kazuma Tamura

发明人： Akira Ookubo ,  Tomohide Koizumi ,  Kazuma Tamura

IPC分类号： B29C67/00

CPC分类号： C08J3/122 ,  B29C64/165 ,  B33Y10/00 ,  B33Y70/00 ,  C08J2339/06 ,  Y10T428/2982

摘要： The present invention provides a powder for molding that reduces or prevents drawbacks such as unevenness and low fluidity when a mixed powder is used as a powder for molding. The present invention relates to powders for molding including particles in which each particle contains an inorganic component and a water-soluble organic polymer component and methods for producing the same.

摘要翻译： 本发明提供了一种用于模塑的粉末，当使用混合粉末作为模塑粉末时，其减少或防止诸如不均匀性和低流动性的缺点。 本发明涉及成型用粉末，其包含各粒子含有无机成分的粒子和水溶性有机聚合物成分及其制造方法。

公开(公告)号：US20130059151A1

公开(公告)日：2013-03-07

申请号：US13277869

申请日：2011-10-20

申请人： Masashi Konishi ,  Shouichi Oonishi ,  Akira Ookubo ,  Masashi Yunoki ,  Ariumi Kawamoto

发明人： Masashi Konishi ,  Shouichi Oonishi ,  Akira Ookubo ,  Masashi Yunoki ,  Ariumi Kawamoto

IPC分类号： C01F5/02 ,  B32B5/16

CPC分类号： C01F5/06 ,  C01F5/02 ,  C01F5/08 ,  C01P2004/61 ,  C01P2006/10 ,  C01P2006/12 ,  C01P2006/19 ,  C01P2006/60 ,  C01P2006/90 ,  Y10T428/2982

摘要： Provided is a magnesium oxide for pharmaceutical use that, when mixed with a drug that is unstable in acid, demonstrates high stabilizing effects on the drug while also demonstrating superior stability of the magnesium oxide per se. The magnesium oxide for pharmaceutical use is used by being mixed with a drug that is unstable in acid, and has a specific surface area as determined according to the BET method of 20 m2/g to 200 m2/g and a degree of activation of 40 Img/g to 200 Img/g.

摘要翻译： 本发明提供一种药物用氧化镁，当与酸不稳定的药物混合时，对药物显示出高的稳定化作用，同时也表现出优异的氧化镁本身的稳定性。 通过与酸不稳定的药物混合使用，并且根据BET法测定的比表面积为20m 2 / g〜200m 2 / g，活化度为40 1g / g至200ml / g。